Molecular mechanisms of viral inhibitors of RIG-I-like receptors

Trends in Microbiology

Volumn 20, Issue 3, 2012, Pages 139-146

  Leung, Daisy W ^a   Basler, Christopher F ^b   Amarasinghe, Gaya K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; NONSTRUCTURAL PROTEIN 1; RETINOIC ACID INDUCIBLE PROTEIN I; TRIM25 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EBOLA VIRUS; GENE EXPRESSION PROFILING; GENE REPRESSION; HOST CELL; INFLUENZA VIRUS A; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VACCINIA VIRUS; VIRUS MORPHOLOGY;

ANIMALS; HUMANS; IMMUNE SYSTEM; RECEPTORS, PATTERN RECOGNITION; VIRUS DISEASES; VIRUSES;

EID: 84857995280     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2011.12.005     Document Type: Review

References (75)

1. Kumar H., et al. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30:16-34.
2. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
3. Wilkins C., Gale M. Recognition of viruses by cytoplasmic sensors. Curr. Opin. Immunol. 2010, 22:41-47.
4. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
5. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
6. Pichlmair A., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
7. Schlee M., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
8. Schmidt A., et al. 5'-Triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12067-12072.
9. Saito T., Gale M. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 2008, 205:1523-1527.
10. Pichlmair A., et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 2009, 83:10761-10769.
11. Kato H., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
12. Yoneyama M., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 2005, 175:2851-2858.
13. Kato H., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205:1601-1610.
14. Schlee M., et al. Approaching the RNA ligand for RIG-I?. Immunol. Rev. 2009, 227:66-74.
15. Schlee M., Hartmann G. The chase for the RIG-I ligand - recent advances. Mol. Ther. 2010, 18:1254-1262.
16. Rothenfusser S., et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol. 2005, 175:5260-5268.
17. Saito T., et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:582-587.
18. Civril F., et al. The RIG-I ATPase domain structure reveals insights into ATP-dependent antiviral signalling. EMBO Rep. 2011, 12:1127-1134.
19. Kowalinski E., et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 2011, 147:423-435.
20. Luo D., et al. Structural insights into RNA recognition by RIG-I. Cell 2011, 147:409-422.
21. Jiang F., et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 2011, 479:423-427.
22. Gack M.U., et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007, 446:916-920.
23. Inn K.S., et al. Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. Mol. Cell 2011, 41:354-365.
24. Zeng W., et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 2010, 141:315-330.
25. Sun Q., et al. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 2006, 24:633-642.
26. Shaw M.L., Palese P. Orthomyxoviridae: The viruses and their replication. Fields Virology 2007, 1647-1689. Lippincott Williams & Wilkins. 5th edn. D.M. Knipe (Ed.).
27. Ehrhardt C., et al. Interplay between influenza A virus and the innate immune signaling. Microbes Infect. 2010, 12:81-87.
28. Fernandez-Sesma A., et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J. Virol. 2006, 80:6295-6304.
29. Garcia-Sastre A., et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252:324-330.
30. Fernandez-Sesma A. The influenza virus NS1 protein: inhibitor of innate and adaptive immunity. Infect. Disord. Drug Targets 2007, 7:336-343.
31. Chen Z., et al. Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J. 1999, 18:2273-2283.
32. Nemeroff M.E., et al. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol. Cell 1998, 1:991-1000.
33. Hornung V., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
34. Mibayashi M., et al. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol. 2007, 81:514-524.
35. Opitz B., et al. IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell Microbiol. 2007, 9:930-938.
36. Ludwig S., et al. The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J. Virol. 2002, 76:11166-11171.
37. Talon J., et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 2000, 74:7989-7996.
38. Donelan N.R., et al. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 2003, 77:13257-13266.
39. Jiao P., et al. A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J. Virol. 2008, 82:1146-1154.
40. Baum A., et al. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:16303-16308.
41. Bergmann M., et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 2000, 74:6203-6206.
42. Hatada E., et al. Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. J. Virol. 1999, 73:2425-2433.
43. Li S., et al. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 2006, 349:13-21.
44. Lu Y., et al. Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 1995, 214:222-228.
45. Min J.Y., Krug R.M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2'-5' oligo(A) synthetase/RNase L pathway. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7100-7105.
46. Tan S.L., Katze M.G. Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase. J. Interferon Cytokine Res. 1998, 18:757-766.
47. Gack M.U., et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 5:439-449.
48. Bornholdt Z.A., Prasad B.V. X-ray structure of NS1 from a highly pathogenic H5N1 influenza virus. Nature 2008, 456:985-988.
49. Cheng A., et al. Structural basis for dsRNA recognition by NS1 protein of influenza A virus. Cell Res. 2009, 19:187-195.
50. Hale B.G., et al. Structure of an avian influenza A virus NS1 protein effector domain. Virology 2008, 378:1-5.
51. Moss B. Poxviridae: the viruses and their replication. Fields Virology 2007, 2905-2945. Lippincott Williams & Wilkins. 5th edn. D.M. Knipe (Ed.).
52. Perdiguero B., Esteban M. The interferon system and vaccinia virus evasion mechanisms. J. Interferon Cytokine Res. 2009, 29:581-598.
53. Chang H.W., Jacobs B.L. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 1993, 194:537-547.
54. Romano P.R., et al. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol. Cell. Biol. 1998, 18:7304-7316.
55. Davies M.V., et al. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 1993, 67:1688-1692.
56. Rivas C., et al. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology 1998, 243:406-414.
57. Sharp T.V., et al. The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation. Virology 1998, 250:302-315.
58. Liu Y., et al. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity. Virology 2001, 289:378-387.
59. Rogan S., Heaphy S. The vaccinia virus E3L protein interacts with SUMO-1 and ribosomal protein L23a in a yeast two hybrid assay. Virus Genes 2000, 21:193-195.
60. Guerra S., et al. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog. 2008, 4:e1000096.
61. Delaloye J., et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 2009, 5:e1000480.
62. Valentine R., Smith G.L. Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. J. Gen. Virol. 2010, 91:2221-2229.
63. Myskiw C., et al. Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J. Virol. 2009, 83:6757-6768.
64. Zhang P., et al. Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L. J. Virol. 2009, 83:5718-5725.
65. Marq J.B., et al. The double-stranded RNA binding domain of the vaccinia virus E3L protein inhibits both RNA- and DNA-induced activation of interferon beta. J. Biol. Chem. 2009, 284:25471-25478.
66. Zhang P., Samuel C.E. Induction of protein kinase PKR-dependent activation of interferon regulatory factor 3 by vaccinia virus occurs through adapter IPS-1 signaling. J. Biol. Chem. 2008, 283:34580-34587.
67. Basler C.F., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12289-12294.
68. Cardenas W.B., et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 2006, 80:5168-5178.
69. Leung D.W., et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 2010, 17:165-172.
70. Basler C.F., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77:7945-7956.
71. Prins K.C., et al. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 2009, 83:3069-3077.
72. Hartman A.L., et al. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004, 328:177-184.
73. Leung D.W., et al. Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:411-416.
74. Prins K.C., et al. Mutations abrogating VP35 interaction with double-stranded RNA render ebola virus avirulent in guinea pigs. J. Virol. 2010, 84:3004-3015.
75. Kimberlin C.R., et al. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:314-319.